EYLEA is indicated for the treatment of patients with neovascular (Wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to myopic choroidal neovascularisation (myopic CNV).
To view the Prescriber Guide to Intravitreal Injections with EYLEA click here
View the Prescriber Guide Video below
Please provide your patients with the EYLEA Patient Booklet including the audio CD (read out of the Patient Booklet) and the product Patient Information Leaflet.
For further information and additional details on EYLEA,
please see the Summary of Product Characteristics (SmPC).